Posted by Michael Wonder on 07 Dec 2020
Chimerix announces FDA acceptance of new drug application for brincidofovir as a medical countermeasure for smallpox
7 December 2020 - Chimerix today announced that the U.S. FDA has accepted the filing of a new drug application for brincidofovir as a medical countermeasure for smallpox.
The FDA granted priority review and set an action date of 7 April 2021 under the Prescription Drug User Fee Act.
